Immunome (IMNM) Is Up 11.4% After CEO Share Buy And Positive Phase III Data - What's Changed
Immunome (IMNM) recently reported positive Phase III data for its oncology candidate varegacestat, alongside a significant share purchase by its CEO and new employee inducement stock option grants. These developments, coupled with the upcoming FDA filing for varegacestat and an earnings release, are sharpening short-term catalysts for the company. Despite these positive indicators, Immunome remains unprofitable, is priced above many peers, and faces ongoing risks related to financing and potential shareholder dilution.
Immunome CSO Sells Shares: Transaction Details & Company Snapshot - News and Statistics
Immunome's Chief Scientific Officer, Jack Higgins, sold 9,438 shares of company stock for $204,238.32 on April 2, 2026, reducing his direct ownership by approximately 30%. This transaction was part of a pre-arranged trading plan. Immunome is a clinical-stage biotechnology company focused on developing antibody-based therapies for cancer and infectious diseases, with a current market capitalization of $2.40 billion and trailing twelve-month revenue of $6.94 million.
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More
Immunome's Chief Scientific Officer, Jack Higgins, sold 9,438 shares of the company's common stock, valued at approximately $204,000, as part of a pre-arranged Rule 10b5-1 trading plan for diversification purposes. This sale reduced his direct holdings by 30.02% but he remains substantially invested. The article emphasizes that this planned executive sale is less significant than Immunome's upcoming milestones, such as an anticipated Q2 2026 NDA submission for varegacestat and expected IND submissions for other programs.
Immunome Inc (IMNM) CSO Higgins sells $204,238 in stock By Investing.com
Immunome Inc.'s Chief Scientific Officer, Jack Higgins, sold 9,438 shares of common stock for a total of $204,238 on April 2, 2026. This transaction was conducted under a pre-arranged trading plan, with Higgins retaining 22,000 direct shares and indirectly owning additional shares for his children. The sale occurs as Immunome's stock has surged 250% over the past year, and analysts maintain a bullish outlook with price targets suggesting further upside.
A Look At Immunome (IMNM) Valuation After Oncology Progress EPS Upgrades And CEO Insider Buying
Immunome (IMNM) is gaining investor interest due to positive phase III oncology data for varegacestat, potential FDA filing, upgraded earnings estimates, and CEO insider buying. Despite trading at a 3.9x price-to-book ratio, indicating overvaluation compared to peers, a discounted cash flow model suggests the stock is significantly undervalued at $177.14 per share, presenting mixed signals for investors. The company's ongoing losses and reliance on successful trial outcomes remain key risks.
Insider Selling: Immunome (NASDAQ:IMNM) CFO Sells $1,424,800.00 in Stock
Immunome (NASDAQ:IMNM) CFO Max Rosett sold 65,000 shares of the company's stock for $1,424,800.00, reducing his ownership by 54.6%. The sale occurred on April 2nd under a pre-arranged Rule 10b5-1 trading plan. Despite the insider selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $33.45, and institutional investors have significantly increased their positions in the company.
Immunome (IMNM) CSO pre-planned 9,438-share sale under Rule 10b5-1
Immunome Inc.'s Chief Scientific Officer, Jack Higgins, sold 9,438 shares of common stock at $21.64 per share on April 2, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following the sale, Mr. Higgins directly holds 22,000 shares and disclaims beneficial ownership of additional shares held in custodial accounts for his children, which are subject to a lockup agreement.
Immunome (IMNM) CFO exercises 71,561 options and sells 65,000 shares
Immunome Inc.'s Chief Financial Officer, Max Rosett, exercised stock options for 71,561 shares and subsequently sold 65,000 shares in open-market transactions on April 2, 2026, under a pre-arranged Rule 10b5-1 trading plan. The options were exercised at prices of $1.05 and $1.35 per share, while the sales occurred at weighted average prices of $21.91 and $22.48 per share. After these transactions, Rosett directly holds 54,037 Immunome common shares.
Immunome Inc (IMNM) CSO Higgins sells $204,238 in stock
Immunome Inc.'s Chief Scientific Officer, Jack Higgins, sold 9,438 shares of common stock for $204,238 under a pre-arranged trading plan. Despite the insider sale, the company's stock has surged 250% over the past year, and analysts maintain a bullish outlook with price targets suggesting further upside. H.C. Wainwright also initiated coverage with a "Buy" rating, highlighting Immunome's promising oncology assets.
Immunome CFO Rosett sells $1.4m in shares
Immunome CFO Rosett Max sold 65,000 company shares worth approximately $1.4 million on April 2, 2026. This transaction followed the exercise of options for 71,561 shares and occurred under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, Immunome's stock has seen a 250% return over the past year and is considered slightly undervalued by InvestingPro, with analysts maintaining bullish price targets.
Immunome Inc (IMNM) CSO Higgins sells $204,238 in stock
Immunome Inc.'s Chief Scientific Officer, Jack Higgins, sold 9,438 shares of common stock for a total of $204,238 on April 2, 2026, as part of a pre-arranged trading plan. Despite the insider sale, analysts maintain a bullish outlook on IMNM, with price targets ranging from $30 to $40, and the stock has surged 250% over the past year. H.C. Wainwright recently initiated coverage with a Buy rating, highlighting the company's promising oncology assets.
Immunome, Inc. (IMNM) stock price, news, quote and history
This article provides comprehensive financial information for Immunome, Inc. (IMNM), including its stock price, historical data, recent news, and analyst ratings. It details the company's focus on developing antibody-drug conjugates and other oncology therapeutics, highlighting its clinical and preclinical assets. The report also includes performance overview, earnings trends, valuation measures, and comparisons with similar biotechnology companies.
Tema Etfs LLC Has $2.19 Million Position in Immunome, Inc. $IMNM
Tema Etfs LLC has reduced its stake in Immunome, Inc. by 37.1% in Q4, now holding 102,055 shares valued at $2.19 million. Additionally, Director Philip Wagenheim sold 36,800 shares, decreasing his position by 9.06%. Analysts maintain a "Moderate Buy" rating for Immunome with a consensus price target of $33.45.
SG Americas Securities LLC Raises Stock Position in Immunome, Inc. $IMNM
SG Americas Securities LLC significantly increased its stake in Immunome, Inc. (NASDAQ:IMNM) during the fourth quarter, purchasing an additional 153,399 shares. This boost brings their total holdings to 162,168 shares, valued at approximately $3.48 million, representing 0.18% of the company. Despite insider selling by Director Philip Wagenheim, analysts maintain a "Moderate Buy" consensus with an average target price of $33.45.
A Look At Immunome (IMNM) Valuation After Oncology Progress EPS Upgrades And CEO Insider Buying
Immunome (IMNM) is gaining investor attention due to positive Phase III oncology data, potential FDA filing, upgraded earnings estimates, and CEO insider buying. While its price-to-book ratio suggests overvaluation compared to peers, a discounted cash flow model indicates the stock is significantly undervalued, trading 87.7% below an estimated $177.14 per share. Investors are advised to consider both valuation models and ongoing clinical risks/rewards.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. announced that its Compensation Committee granted inducement awards of non-statutory stock options for 188,500 shares to thirteen new employees. These awards, approved on April 1, 2026, are valued at an exercise price of $22.45 per share and will vest over four years, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are intended to incentivize the new hires and are subject to the company’s 2024 Inducement Plan.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Immunome, Inc. announced inducement grants in accordance with Nasdaq Listing Rule 5635(C)(4). The grants are part of the company's compensation efforts and reflect standard practices for attracting employees. This report provides details on these grants as required by Nasdaq regulations.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. announced that its Compensation Committee granted inducement awards of non-statutory stock options to thirteen new employees on April 1, 2026. These options allow them to purchase an aggregate of 188,500 shares of common stock, with an exercise price of $22.45 per share, vesting over four years. This action was taken in accordance with Nasdaq Listing Rule 5635(c)(4) to attract and retain talented individuals.
Proposed common-share sale reported by IMNM (NASDAQ: IMNM)
Immunome Inc. (NASDAQ: IMNM) has submitted a Rule 144 notice regarding proposed sales of common stock. The filing lists a proposed sale of 65,000 shares valued at $4,723,550.00, dated April 2, 2026. The document also details previous transactions including stock option exercises, options granted, and a merger payout spanning from September 2024 to October 2023, with Fidelity Brokerage Services LLC named as the broker for the proposed sale.
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?
Immunome (IMNM) saw a 13.3% increase in its share price due to above-average trading volume and renewed investor optimism surrounding its advancing oncology pipeline. The company's lead asset, varegacestat, showed strong Phase III data, with an FDA filing planned for 2026, and its broader pipeline also looks promising. Analysts anticipate a quarterly loss of $0.60 per share and revenues of $2 million, but positive trends in earnings estimate revisions suggest potential for continued stock appreciation.
Immunome (NASDAQ: IMNM) CSO gifts 6,291 shares, retains 31,438
Immunome Inc.'s Chief Scientific Officer, Jack Higgins, reported a bona fide gift of 6,291 shares of Common Stock, which were valued at $0.00 per share. Following this transaction, Higgins directly owns 31,438 shares, and indirectly holds 1,000 shares in each of three custodial accounts for his children, though he disclaims beneficial ownership of these custodial shares. These custodial shares are also subject to a lockup agreement he entered into on December 15, 2025.
Immunome (IMNM) Surges by 13.3%: Can This Momentum Continue?
Immunome, Inc. (IMNM) saw a 13.3% increase in its stock price, closing at $21.87, attributed to positive developments in its oncology pipeline, particularly with lead candidate varegacestat and expanding ADC projects. Despite projected quarterly losses, investor confidence is boosted by a 7.6% upward revision in consensus earnings estimates for the upcoming quarter. The company, which holds a Zacks Rank #3 (Hold), is preparing for a potential FDA submission in 2026.
Goldman Sachs Initiates Coverage of Immunome (IMNM) with Buy Recommendation
Goldman Sachs has initiated coverage on Immunome (IMNM) with a Buy recommendation. This move suggests a positive outlook from the investment bank regarding Immunome's future performance and potential as an investment. No further details about the rating or price target were provided in this snippet.
Immunome (IMNM) Surges by 13.3%: Can This Momentum Continue?
Shares of Immunome, Inc. (IMNM) recently surged by 13.3% driven by renewed investor optimism surrounding its oncology pipeline, particularly positive Phase III results for varegacestat and a broadening drug development program. Despite projected quarterly losses and revenue decreases, analysts have increased earnings per share estimates for the upcoming quarter, which historically correlates with short-term price gains. Investors are advised to monitor IMNM's momentum, as the company currently holds a Zacks Rank #3 (Hold).
Goldman Sachs Initiates Coverage of Immunome (IMNM) with Buy Recommendation
Goldman Sachs has initiated coverage of Immunome (IMNM) with a Buy recommendation. This suggests a positive outlook from the investment bank regarding the biotechnology company's future performance and potential.
Insider Buying: Clay Siegall Acquires Shares of Immunome Inc (IMNM)
Clay Siegall, President and CEO of Immunome Inc, recently purchased 25,450 shares, increasing his total holdings to 690,704 shares. This transaction is part of a larger trend of insider buying at Immunome, with 83,968 shares acquired in the past year by insiders and no sales. Immunome Inc (IMNM) shares were trading at $19.67, with a market cap of $2.317 billion, but the stock is considered significantly overvalued based on its GF Value of $2.85.
Immunome (NASDAQ:IMNM) Stock Price Up 9.4% - What's Next?
Immunome (NASDAQ:IMNM) saw its stock price jump 9.4% in mid-day trading on Tuesday, though volume was significantly lighter than average. Despite this rise, the company's fundamentals remain challenged, with a recent EPS miss, deeply negative margins, and an insider selling shares. Analyst sentiment is generally positive, with a "Moderate Buy" consensus and an average price target of $33.45.
Immunome CEO Clay Siegall buys $500k in shares By Investing.com
Immunome Inc. CEO Clay B. Siegall recently purchased 25,450 shares of common stock for over $500,000, bringing his total direct ownership to 690,704 shares. This insider transaction follows a significant 187% surge in the stock over the past year. Analysts from H.C. Wainwright have initiated coverage with a Buy rating and a $40 price target, citing Immunome's strong oncology asset portfolio.
Immunome CEO Clay Siegall buys $500k in shares By Investing.com
Immunome Inc. CEO Clay B. Siegall recently purchased 25,450 shares of the company's common stock for over $500,000. This comes as the stock has seen a significant 187% surge over the past year, although it retains high volatility. Analysts, including H.C. Wainwright, maintain an optimistic outlook for Immunome, setting price targets between $30 and $40, citing the company's oncology asset portfolio.
Immunome (IMNM) CEO adds 25,450 shares in $19.67 stock purchase
Immunome Inc. (IMNM) President and CEO, Clay B. Siegall, purchased 25,450 shares of Common Stock in an open-market transaction on March 27, 2026. The shares were acquired at a weighted average price of $19.67, with individual prices ranging from $19.63 to $19.70. This purchase increased his direct holdings to 690,704 shares, signaling a positive sentiment from the CEO.
Immunome CEO Clay Siegall buys $500k in shares
Immunome Inc. CEO Clay B. Siegall recently purchased 25,450 shares of the company's stock for over $500,000. This insider transaction comes as the stock has seen a significant surge over the past year, and analysts maintain an optimistic outlook with price targets between $30 and $40. H.C. Wainwright also initiated coverage with a Buy rating, highlighting the company's oncology assets, particularly varegacestat.
Immunome Inc Stock: Clinical-Stage Biotech Targeting Cancer and Infectious Diseases with Innovative Antibody Platform
Immunome Inc, a clinical-stage biotechnology company listed on Nasdaq (IMNM), is developing next-generation therapeutics for cancer, autoimmune diseases, and infectious diseases using its proprietary human memory B-cell based Discovery Engine platform. The company's strategy involves advancing its pipeline candidates like AL102 and other bispecific antibodies, with a focus on achieving clinical milestones and securing partnerships. Immunome's financial health, characterized by a lean capital structure and insider ownership, positions it as a growth-oriented play for North American investors despite inherent biotech sector risks.
Immunome Inc Stock: Clinical-Stage Biotech Targeting Cancer and Infectious Diseases with Innovative Antibody Platform
Immunome Inc (NASDAQ: IMNM) is a clinical-stage biotechnology company utilizing its proprietary Discovery Engine platform to develop novel antibody-based therapeutics for oncology, autoimmune diseases, and infectious diseases. The company's business model relies on milestone payments, royalties, and direct commercialization, with financial health supported by equity raises and strategic partnerships. Investors are advised to monitor pipeline milestones and data readouts for potential valuation changes, while acknowledging the inherent risks of early-stage biotech.
Don't Ignore The Insider Selling In Immunome
A recent insider sale at Immunome by Director Philip Wagenheim, totaling US$1.3 million at an average price of US$20.55, has raised some caution. While the transaction reduced his holding by 16%, the article notes that over the last year, Immunome insiders have been net buyers overall. The article also highlights that insiders own 1.1% of the company, valued at US$26 million.
Vanguard disaggregates holdings; IMNM shows 0 shares after realignment (IMNM)
The Vanguard Group filed an amended 13G/A, reporting 0 beneficial shares of Immunome Inc. (IMNM), representing 0% of the class. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately, as per SEC Release No. 34-39538. This reporting change is administrative and does not indicate a sale of shares by Vanguard.
Don't Ignore The Insider Selling In Immunome
A director at Immunome (NASDAQ:IMNM) recently sold US$1.3m worth of shares, reducing their total holding by 16%. While there's been more insider selling than buying in the last three months, overall insider activity for the past year shows net buying, and insiders still hold 1.1% of the company, valued at US$26m. The article suggests caution regarding the recent selling but notes the overall positive insider buying trend over the last year.
Why Immunome Stock Is Suddenly Racing Higher
Immunome (IMNM) shares are experiencing a surge due to investor optimism surrounding its lead oncology candidate, varegacestat, following strong Phase 3 results and a planned New Drug Application in Q2 2026. This positive sentiment is further boosted by bullish analyst ratings, including a $40 price target from H.C. Wainwright, and reassurance from the company's substantial cash balance, which is projected to fund operations through 2028.
Immunome Insider Sold Shares Worth $1,335,626, According to a Recent SEC Filing
An insider at Immunome, Inc. recently sold shares valued at $1,335,626, as per a recent SEC filing. This transaction was reported on March 24, 2026, and follows other recent news for the biotechnology company, including lock-up agreement endings and earnings reports. Immunome focuses on developing targeted cancer therapies using its memory B cell hybridoma technology.
Director Philip Wagenheim Sells 65,000 Shares of Immunome Inc (I
Philip Wagenheim, a Director at Immunome Inc (IMNM), sold 65,000 shares of the company on March 23, 2026, bringing his total holdings to 341,147 shares. This transaction adds to a year of insider selling for Wagenheim, with no recorded purchases. The stock, trading at $20.55, is considered significantly overvalued with a price-to-GF-Value ratio of 7.19, against an estimated GF Value of $2.86.
Philip Wagenheim Sells 36,800 Shares of Immunome (NASDAQ:IMNM) Stock
Immunome Director Philip Wagenheim sold a total of 65,000 company shares in two recent transactions (36,800 shares on March 20th and 28,200 shares on March 23rd), decreasing his stake by 9.06%. While Immunome missed its quarterly EPS estimates and remains unprofitable, analysts maintain a "Moderate Buy" consensus rating with an average target price of $33.45 against a current trading price of around $20.75. Hedge funds and institutional investors have also recently adjusted their positions in the company.
Immunome (NASDAQ:IMNM) Director Philip Wagenheim Sells 28,200 Shares
Immunome Director Philip Wagenheim sold 28,200 shares of the company's stock on March 23, following a previous sale of 36,800 shares on March 20, significantly reducing his holdings. The company's shares traded up 3.7% to $20.75, despite reporting an EPS loss of $0.75 which missed estimates. Analysts, however, maintain a "Moderate Buy" rating with an average price target of $33.45.
Immunome Director Sold Shares Worth Over $1.3M
Immunome Director Wagenheim Philip reported two direct sales of company common stock on March 20 and March 23, 2026. The sales totaled over $1.3 million, with weighted average prices of $20.47 and $20.65 respectively. Following these transactions, Philip Wagenheim still directly owns 341,147 shares of Immunome.
Immunome (IMNM) director sells 65,000 shares in open market
Immunome Inc. director Philip Wagenheim sold a total of 65,000 shares of company common stock in two open-market transactions on March 20 and March 23, 2026. The sales were executed at weighted average prices of $20.47 and $20.65 per share, respectively. Following these transactions, Wagenheim directly holds 341,147 shares of Immunome Common Stock.
IMNM PE Ratio & Valuation, Is IMNM Overvalued
The article analyzes Immunome Inc (IMNM)'s valuation, stating it is in the "Fair zone" with a forward PS ratio of 1004.20, considered fair compared to its five-year average. According to the relative valuation method, IMNM's fair price ranges from $5.70 to $22.63. The company's P/S ratio is significantly above the industry average, which the article suggests is unsustainable given its robust revenue growth of -100.00%.
Immunome Inc stock surges on breakthrough oncology data, drawing DACH biotech investor interest
Immunome Inc. stock surged following positive Phase 1 results for its lead cancer vaccine candidate, IMNN-101, which showed strong immune responses in patients with advanced solid tumors. The Nasdaq-listed biotech firm's progress in targeted immunotherapies, coupled with a robust pipeline and strong financial position, is attracting significant interest from DACH (Germany, Austria, Switzerland) investors seeking high-growth opportunities in precision oncology. Despite potential biotech market volatility and competitive risks, analysts project considerable appreciation based on current data and strategic partnerships like the one with Merck.
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of "Moderate Buy" by Analysts
Immunome, Inc. (NASDAQ:IMNM) has received a "Moderate Buy" consensus recommendation from eleven analysts, with an average 12-month price target of $33.45. Despite missing quarterly EPS targets, the company's shares opened at $20.02, and institutional ownership has grown significantly, with major additions from T. Rowe Price and Vanguard. Insider transactions show a director selling shares while the CEO purchased shares, reflecting mixed internal sentiment alongside the positive analyst outlook.
Form 144 Immunome Inc. For: 20 March
This article provides details on Form 144 for Immunome Inc., specific to March 20. It includes a general disclaimer about the risks associated with trading financial instruments and cryptocurrencies, emphasizing market volatility and the importance of informed decision-making. The content also notes that data provided may not be real-time or accurate and advises thorough research before investing.
Behavioral Patterns of IMNM and Institutional Flows
The article analyzes Immunome Inc. (NASDAQ: IMNM) through AI-generated signals, highlighting weak near- and mid-term sentiment but a strong long-term outlook. It presents three institutional trading strategies (position, momentum breakout, risk hedging) with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for IMNM.
HC Wainwright & Co. initiates coverage of Immunome (IMNM) with buy recommendation
HC Wainwright & Co. has initiated coverage of Immunome (IMNM) with a buy recommendation. This signals a positive outlook on the company's stock from the investment banking firm. Investors may want to consider this new analyst rating as part of their research into Immunome.
Immunome Inc Stock (ISIN: US45254C1062) Eyes Upside as Lock-Up Expires Today Amid Short-Term Buy Sig
Immunome Inc (IMNM), a clinical-stage biotech company, is at a critical juncture as a 91-day lock-up on certain stock options expires on March 17, 2026. Despite recent price weakness, short-term technical indicators suggest a buy opportunity with a projected 21.27% upside over the next three months. The lock-up expiration could introduce selling pressure, but the company's proprietary B-cell platform for antibody therapeutics offers differentiation in the competitive immunotherapy field.
